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Introduction
The emphysematous phenotype of Chronic obstructive 
pulmonary disease (COPD), with smoking as the main 
etiology has an estimated global prevalence of 1.8% (1). 
The pathogenic mechanism of emphysema is destruction 
of alveolar walls, irreversible airway obstruction, loss 
of elastic recoil, air trapping, and thus a reduced gas 
exchange area. Clinical prognosis and quality of life in 
end-stage emphysema is very poor, with concomitant 
diseases increasing the risk of potentially life-threatening 
complications. Symptoms in emphysema-dominant patients 
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are associated with dyspnea driven by lung hyperinflation 
(static and dynamic), and reduction of hyperinflation by 
reducing lung volume in the most diseased area of the lung 
is the objective of therapeutic intervention (2). 
Optimal medical management of emphysema includes 
smoking cessation, pulmonary rehabilitation and physical 
activity training, supplemental oxygen as required, and 
pharmacotherapy. Nevertheless, symptoms such as dyspnea 
and impaired quality of life may become overwhelming 
and, thus, invasive treatment strategies, such as lung 
transplantation and lung volume reduction (LVR) are 
indicated. Only a minority of patients are suitable for 
lung transplantation due to shortage of donor organs, 
comorbidities and advanced age (in Switzerland 54 COPD 
patients underwent lung transplantation between 1993 and 
2007) (3). Therefore, LVR is a promising treatment option 
in emphysema patients with hyperinflation. Lung volume 
reduction by surgery (LVRS) has been shown to improve 
lung function, 6MWD and quality of life in a subset of 
patients (2). However, postoperative morbidity and mortality 
remain concerns for this frail population, and LVRS has 
not been shown to benefit patients with homogenous 
disease. Several bronchoscopic lung volume reduction 
(BLVR) procedures have been intensively investigated in 
randomized trials. BLVR using endobronchial coils and 
valves are included in the GOLD2017 guidelines and are 
routinely applied throughout Europe (4).
The PneumRx® Endobronchial Coils have been 
demonstrated in three randomized, controlled trials to 
improve quality of life, exercise tolerance, and lung function 
in bilaterally treated patients (5-7). The coils are shape-
memory nitinol implants bronchoscopically deployed into 
the areas of lung parenchyma most damaged by emphysema 
(8,9). Coils improve lung function by reducing lung 
volume and tethering airways, restoring airway patency and 
reducing airway collapse during exhalation and exercise 
(5,10). Because the coil acts by a simple mechanical action 
and is not a blocking device, these effects are achieved 
immediately irrespective of collateral ventilation. This 
device is deployed via a simple catheter-based delivery 
system through a fiber-optic bronchoscope and requires no 
incision. 
Methods
The PneumRx European registry (NCT01806636) is a 
prospective post market multi-center registry of patients 
treated in routine clinical practice throughout Europe. 
Inclusion and exclusion criteria are in accordance with the 
company’s Instructions for Use (IFU) and indications for 
coil therapy. Registry participants are patients scheduled to 
undergo coil treatment who consent to have their clinical 
data collected in the Registry. All patients had provided 
informed consent before undergoing treatment. Protocols 
and consent forms were approved by the local Ethics 
committees (Lead EC: Commission cantonale d’éthique 
de la recherche CCER, Geneva, ID: GE 14–017) prior to 
study enrollment. Data were de-identified and captured on 
web-based electronic Case Report Forms (eCRFs). The 
study is conducted under EEC MDD, EN ISO 14155:2011 
and all applicable local regulations.
In Switzerland, coil therapy is used in 6 expert centers 
(Inselspital Bern, L’hôpital Neuchâtelois-Pourtalès, 
Hôpitaux Universitaires de Genève, Lungenzentrum 
Hirslanden, University Hospital Zurich, Centre Hospitalier 
Universitaire Vaudois). All treating physicians are board-
certified pulmonologists with interventional experience, 
and all received procedural training from the company. 
Participating sites have facilities that support the practice 
of interventional bronchoscopy and are able to perform 
comprehensive patient screening and selection as well 
as postoperative patient management. Patients had 
severe emphysema, were on optimal medical therapy, 
and ideally had completed pulmonary rehabilitation 
and smoking cessation prior to consenting to treatment. 
Patients underwent high resolution CT scanning to assess 
emphysema distribution and exclude suspicious findings, 
such as nodules suspicious for lung cancer, bronchiectasis, 
and severe bullous disease. 
Study population
Adul t  pa t ient s  d iagnosed  wi th  homogeneous  or 
heterogeneous emphysema who were appropriate for coil 
treatment based on the CE-Mark Approved IFU and who 
have been scheduled for coil treatment were considered 
candidates for the registry. Patients had residual volume 
(RV) of at least 175% predicted, post bronchodilator 
forced expiratory volume in 1 second (FEV1) of ≤45% 
predicted and a normal international normalized ratio 
(INR) in the absence of anticoagulation therapy. Patients 
were not eligible for the coil treatment if they had known 
uncontrolled pulmonary hypertension defined by systolic 
RV pressure >50 mmHg, giant bullae >1/3 lung volume, 
and were on antithrombotic treatment (except for aspirin) 
which could not be stopped 7 days prior to treatment. All 
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patients who were treated with coils since October 2013 
were enrolled in the Swiss registry. 
Devices and procedures
Endobronchial coils are available in 3 lengths: 100, 125, and 
150 mm. The coil delivery system consists of a cartridge 
to house the straightened coil for deployment, a catheter 
for deployment, a guidewire and a specialized forcep for 
release or retrieval of the coil. The deployment procedure 
has been previously described (10). The peri-procedural 
patient management (e.g., prophylactic treatment, 
control chest X-ray(s) or CT(s), or post procedural 
control bronchoscopies) is left to the discretion of the 
treating physician to adhere to local standards for patient 
management following bronchoscopic interventions, and 
was not captured in the registry. 
Follow-up
Per the Registry protocol, post-procedure patient follow-
up was based on the individual institution’s standard of care. 
Registry specific follow-up visits were recommended at 
6 months and 12 months, and then annually up to 3 years 
counted from the date of the first procedure. The baseline 
visit included medical examination, pulmonary function 
tests (body plethysmography, spirometry), 6-minute walk 
test (6MWT) on room air or carrying oxygen when needed, 
and medication history. Quality of life (QOL) was assessed 
by the St. George`s Respiratory Questionnaire (SGRQ) 
and dyspnea by the modified Medical Research Council 
(mMRC) 5-level dyspnoea scale. All baseline, procedure, 
and follow-up data were collected via eCRFs and entered 
into the electronic data capture (EDC) database. Adverse 
events were recorded at each study visit.
Study endpoints
The primary endpoint of this study was the change in 
quality of life from baseline to post treatment follow-
up as assessed by the SGRQ (total points). Secondary 
endpoints included changes in lung function measurements 
[(RV) (L), RV/total lung capacity (TLC) (%), FEV1 (L), 
FEV1/forced vital capacity (FVC) (%)] and changes in 
exercise capacity assessed by the 6MWT between baseline 
and post treatment follow-up. 
Responder rates were evaluated using the minimal 
clinical important differences (MCIDs) that have been 
reported for FEV1, L +10% (11), RV −0.35 L (12), 6MWD 
+26 m (13), and SGRQ −4 points total score (14).
Safety endpoints included occurrence of serious adverse 
events (SAE) including any device malfunction or failures.
Statistical analyses
Patient demographics, baseline characteristics, procedure 
characteristics, device usage and hospital stay are 
summarized using descriptive statistics. Serious Adverse 
events (SAEs) are summarized by number and percent of 
subjects as well as number of events for the Treatment 
Recovery Period (30 Days following either procedure), 
31–91, 92–182, and through 6 months of follow-up. 
Effectiveness data is summarized using descriptive statistics. 
Results at 6-month follow-up were compared to baseline 
values and analyzed using paired t-test for continuous 
variables (alpha level 0.05). No adjustments were made for 
multiple comparisons.
Results
Twenty-nine patients had completed bilateral treatment and 
had completed a 6-month follow-up visit between October 
2013 and November 2016 (Figure 1). Of these, an additional 
two patients died (both prior to the 6-month follow-up 
visit).
Baseline and treatment characteristics of the patients 
in this analysis are shown in Table 1. Sixty-nine percent 
of patients had heterogeneous emphysema as determined 
by investigators and 31% had homogeneous emphysema. 
These patients had very advanced emphysema with severe 
hyperinflation, with mean FEV1 30% pred., and RV 247% 
pred. They were functionally limited with very poor quality 
of life, with mean 6MWD of 272 m, and mean SGRQ 
score of 57 points. Pulmonary rehabilitation status was 
documented in 14/29 (48%) patients, of whom 9 (64%) 
had completed pulmonary rehabilitation. Patients received 
mean 23 coils in two separate procedures and completed the 
6-month post treatment follow-up visit at median 204 days 
(range, 124 to 272 days). The median hospital stay after 
each coil procedure was 1.0 day; mean procedure time was 
47 minutes which included 15 minutes under fluoroscopy.
At  6  months ,  pa t i en t s  r epor ted  cons iderab le 
improvement in their quality of life following bilateral 
coil treatment. SGRQ decreased by −13.9±11.9 points 
compared to baseline (P<0.0001) (Table 2), with an 87% 
SGRQ responder rate. 61% of patients achieved twice the 
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64  
Enrolled patient in Switzerland  
between Oct. 2013 and Nov. 2016 
2 
Patient died prior to reaching 6M FU 
•  I unilaterally treated patient 
following Ml 
•  I bilaterally treated patient due to 
unknown cause 
20  
Patients not yet finished bilateral 
treatment 
13  
Patients not yet completed 6M FU 
29 
Completed 6M FU 
Figure 1 Patient accountability. FU, follow-up.
MCID in SGRQ response (≥8 points decrease) (Table 3). 
Patients demonstrated significant increases in 6MWD, 
with mean increase of 53.4±66.9 m (P=0.0021) (Table 2). A 
6MWD responder rate of 60% was observed at 6-month 
follow-up (Table 3). 
FEV1 increased by 0.14±0.22 L at 6 months (P=0.0021), 
with 57% of patients achieving MID level response at 10% 
threshold. RV decreased by −0.91±1.04 L at 6 months 
compared to baseline (P=0.0002); 76% of patients achieved 
the MID of −0.35 L. The RV/TLC [%] also showed a 
statistically significant decrease at 6 months after treatment 
(mean change −7.72±11.19; P=0.0021).
A total of 7 SAEs were reported in 6 of 29 bilaterally 
treated patients (Table 4) through 6 months; 5 SAEs 
occurred within the first 30 days of either treatment 
[1 pneumonia, 2 pneumothorax, 1 acute myocardial 
infarction (MI), 1 chest pain]. Two patients developed 
pneumonia after 30 days but within the 6-month follow-
up period. All SAEs were resolved. Among the total Swiss 
registry population of 64 patients, two deaths were reported 
within the 6-month follow-up (1 myocardial infraction, one 
unconfirmed cause of death); neither was deemed procedure 
or device related. No device removals were necessary.
Discussion
We present our experience with endobronchial coil 
treatment as part of routine clinical practice in Switzerland. 
The key limitation of this analysis is the small population 
of patients with completed 6-month follow-up; however, 
real-world effectiveness as well as real-world challenges 
of patient follow-up are important to integration of novel 
therapeutic approaches, and should be described. Because 
there was no control arm, a placebo effect cannot be ruled 
out, nor can responder bias. However, the RENEW trial 
reported outcomes in coil treated patients vs. a control arm, 
with statistically significant between-group differences in 
6MWD, FEV1, SGRQ, and RV/TLC favoring the coil 
treatment group at one-year post treatment, and a highly 
clinically significant between-group difference in SGRQ of 
−8.9 points (P<0.001) at 1-year post treatment (7). Because 
not all centers offered alternate endoscopic lung volume 
reduction treatment options, a strength of this study is 
avoidance of selection bias, whereby patients with severe 
hyperinflation and highly heterogenous disease (presumably 
the optimal “responder profile”) might be directed 
toward other therapies while patients with homogenous 
disease, who typically demonstrate lower magnitude of 
benefit, might preferentially be directed toward coils. Our 
physiologic outcomes in patients treated with endobronchial 
coils are in fact comparable to 6-month published outcomes 
in the post-market setting for a larger cohort treated with 
endobronchial valves (15).
A strength of this analysis is that all patients treated 
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Table 1 Baseline characteristics (all patients, N=29)
Baseline parameters n Mean ± SD/n (%) Median Range
Demographics
Age, years 29 65.76±9.27 66 37–83
BMI, kg/m2 29 23.66±4.94 23 16.16–35.56
Gender: female/male 29 18 (62.07)/11 (37.93)
Medical history
Emphysema : heterogeneous/homogeneous 29 20 (68.97)/9 (31.03)
6MWD (m) 23 272.17±88.03 270 107–482
SGRQ (points) 29 56.58±10.36 57 36–76
mMRC (points) 29 2.66±0.77 2
RV (L) 28 5.20±1.35 5 3–8
RV % predicted 28 247.36±57.95 243 147–392
RV/TLC (%) 28 68.78±9.02 69 45–85
FEV1 (L) 28 0.72±0.20 1 0.4–1.1
FEV1 % predicted 28 29.67±7.78 29 17–47
FEV1/FVC (%) 28 36.84±9.49 36 22–59
Prior rehabilitation: yes/no 14 9 (64.29)/5 (35.71)
Procedures
Days between treatments (Tx): Tx1 to Tx2 29 85.45±50.35 82 21–210
Total coils 29 23.24±5.10 22 18–45
Number of coils Tx1 29 11.34±1.54 11 8–15
Number of coils Tx2 29 11.38±2.34 11 6–18
Procedure time (min) post Tx1 29 48.48±23.61 37 20–95
Procedure time (min) post Tx2 28 44.61±21.11 40 20–115
Fluoroscopy time (min) post Tx1 28 14.75±11.93 10 5–45
Fluoroscopy time (min) post Tx2 28 15.93±14.96 10 5–50
Hospital days post Tx1 29 1.79±1.08 1 1–5
Hospital days post Tx2 29 2.41±2.69 1 1–12
6MWD, 6-minute walk distance; BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity, mMRC, 
modified medical research council; RV, residual volume; SGRQ, St. George Respiratory Questionnaire; TX, treatment.
with coils in Switzerland were included in the registry and 
were thus considered in this analysis. Another strength is 
that patients in this multi-center registry achieved a high 
response rate across all 4 endpoints of interest in COPD, 
despite a very broad range of baseline characteristics of 
our patients compared to previously published trials. Our 
median age was 66 but the range is 37 to 83 years, our 
median 6MWD is 270 m with a range of 107 to 482 m, 
our median RV% pred. is 247% with a range of 147% 
to 392%, and our FEV1% pred. is 29% with a range of 
17–47%. We believe our data suggest that careful and 
holistic patient selection, taking into account the patient’s 
medical (including psychosocial) history, exacerbation 
history, stability of other comorbidities, and commitment 
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Table 2 Efficacy results: change from baseline at 6-month FU (all patients, N=29)
Change from baseline at 6-month FU n Mean ± SD P for all groups
6MWD (m) 20 53.40±66.92 0.0021
SGRQ (points) 23 −13.88±11.89 <0.0001
FEV1 (L) 28 0.14±0.22 0.0021
FEV1/FVC (%) 28 −0.46±6.01 0.6909
RV (L) 25 −0.91±1.04 0.0002
RV/TLC (%) 25 −7.72±11.19 0.0021
6MWD, 6-minute walk distance; FEV1, forced expiratory volume in 1 second; FU, follow-up; FVC, forced vital capacity, RV, residual 
volume; SGRQ, St. George Respiratory Questionnaire; TLC, total lung capacity.
Table 3 Efficacy results: responder rates (MCID) at 6-month FU for bilaterally treated patients (all patients)
MCID responder rates at 6-month FU n/N Percent
6MWD responder (≥26 m) 12/20 60.0
SGRQ responder (≥4 points) 20/23 87.0
SGRQ responder (≥8 points) 14/23 60.9
RV responder (≥0.35 L) 19/25 76.0
FEV1 responder (≥10%) 16/28 57.0
Two or more MCIDs responder^ 21/29 72.4
^, at least two MCID responses among 6MWD, SGRQ (4 points), FEV1 and RV; missing values have been counted as non-response. 
6MWD, 6-minute walk distance; FEV1, forced expiratory volume in 1 second; FU, follow-up; MCID, minimal clinically important difference; 
RV, residual volume; SGRQ, St. George Respiratory Questionnaire.
Table 4 SAEs of interest (all patients N=29)
SAEs of interest
Subjects, 0–30 d post 
Tx1, n (%)
Events, 0–30 d post 
Tx1 (n)
Through 6 months subjects 
(0–182 d post Tx1) n (%)
Through 6 months events 
(0–182 d post Tx1), n
Total 5 (17.24) 5 6 (20.69) 7
Acute myocardial infarction 1 (3.45) 1 1 (3.45) 1
Chest pain 1 (3.45) 1 1 (3.45) 1
Pneumonia 1 (3.45) 1 3 (10.34) 3
Pneumothorax 2 (6.90) 2 2 (6.90) 2
SAEs, serious adverse events; TX, treatment.
to self-care may be a stronger predictor of good outcomes 
than any particular baseline factor. Due to the complexity 
and variability of the severe emphysema patient profile, 
we also deemed notable that 72% of our patients achieved 
at least 2 MCID level responses among the 4 outcomes of 
interest (SGRQ, 6MWD, FEV1 and RV) (Table 3). Since 
endobronchial trials tend to demonstrate high SGRQ 
improvements, we consider a “2 or more MCID” threshold 
as potentially indicative of overall “responsiveness”, where 
either a functional or physiologic endpoint supports the 
patient’s reported improvement in quality of life.
Our data represents the first analysis of coil therapy 
implemented in centers of excellence throughout 
Switzerland. We believe that some learnings can be 
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derived from these data. As previously described, a factor 
influencing responsiveness to lung volume reduction 
is heterogeneity of emphysema (2,16). Patients with 
homogenous disease are generally not candidates for lung 
volume reduction surgery, endobronchial valves, or other 
non-implant therapies under clinical investigation (i.e., 
steam or glue). However, in the RENEW randomized 
coil trial, 77% of patients had homogeneous emphysema 
based on visual assessment (7). In our registry, 67% of 
patients have heterogeneous emphysema, supporting the 
notion that heterogeneity may predict larger magnitudes of 
improvement from any intervention, and that therapeutic 
success must be considered from the perspective of the 
patient (i.e., quality of life improvement) and the limitations 
of the disease profile (i.e., other comorbidities or degree of 
heterogeneity).
In Switzerland, single photon emission computed 
tomography (SPECT) perfusion is part of the standard 
diagnostic work up for patients who are evaluated for lung 
volume reduction procedures. Because LVRS and lobar 
blocking therapies “disconnect” the treated/resected area 
from ventilation, perfusion status plays a critical role in 
determining optimal lobe targets. The situation is less 
clear for coil treatment, which is not a blocking therapy, 
and hence treated lobes remain ventilated. In Switzerland, 
patients were treated based on visual assessment of the 
emphysema, combined with semi-quantitative SPECT 
perfusion analysis. Patients usually received treatment in the 
lobes with the lowest perfusion, which is typically associated 
with areas of higher emphysematous destruction; however, 
this was left to the discretion of the treating physician. 
SPECT data were not captured in the registry and 
quantitative CT (qCT) analyses were not performed. Thus, 
it remains speculative if SPECT and qCT to determine 
lobe targeting for coils might have contributed to the very 
good effectiveness data in this study. 
Conclusions
Endobronchial coil therapy in Switzerland is safe and yields 
very high 6-month responder rates across all relevant outcome 
measures. Our findings suggest that endobronchial coil 
therapy is an excellent therapeutic option for carefully selected 
patients when offered in experienced interventional centers.
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